Background and Objectives Buprenorphine's high‐binding affinity as a partial µ‐opioid
agonist displaces preexisting full agonists causing precipitated withdrawal, which requires …

Background/objectives Micro-induction is a novel buprenorphine induction approach that
seeks to avoid withdrawal and minimize precipitated withdrawal, both barriers to standard …

Background and Objectives Buprenorphine/naloxone has been shown to be effective in the
treatment of opioid use disorder. Due to its pharmacological properties, induction can be …

1. Bruneau J, Ahamad K, Goyer M-È, et al. Management of opioid use disorders: a national
clinical practice guideline. CMAJ 2018; 190: E247-57. 2. McClain DA, Hug CC Jr …

Abstract Introduction and Aims Buprenorphine/naloxone is an evidence‐based treatment for
opioid use disorder, but an identified limitation is the period of required opioid abstinence …

Background Buprenorphine is a partial µ-opioid receptor agonist used for maintenance
treatment of opioid dependence. Because of the partial agonism and high receptor affinity, it …

Although expanding the availability of buprenorphine—a first-line pharmacotherapy for
opioid-use disorder (OUD)—has increased the capacity of healthcare systems to offer …

Objectives: Patients with opioid use disorder (OUD) can initiate buprenorphine without
requiring a withdrawal period through a low-dose (sometimes referred to as “micro …

Low dose buprenorphine initiation, is an alternative method of initiating buprenorphine in
which the starting dose is very low and gradually increased to therapeutic levels over a …

Buprenorphine possesses many unique attributes that make it a practical agent for adults
and adolescents with opioid use disorder (OUD) and/or acute or chronic pain. Sublingual …